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Abstract
Diastolic heart failure (HF) as defined by the symptoms and signs of HF, preserved ejection
fraction and abnormal diastolic function is estimated to occur in half of all patients presenting
with HF. Patients with preserved ejection fraction are older and more often female. The
underlying etiology of HF differs, with hypertension being more common in patients with
preserved ejection fraction and ischemic heart disease predominant among those with reduced
ejection fraction. Diastolic HF is associated with high mortality comparable with that of HF
with depressed ejection fraction with a five year survival rate after a first episode of 43% and
a higher excess mortality compared with the general population. Despite significant disease
burden, clinical and biological prognostic factors in diastolic HF remain poorly understood.
There is limited data from well designed studies regarding the effective treatment strategies for
this group of patients. The purpose of this review is to summarize the mortality data and
predictors of mortality in patients with diastolic HF for better understanding of the prognosis.
In patients with diastolic HF older age, male gender, non-Caucasian ethnicity, history of
coronary artery disease and atrial fibrillation are associated with poor prognosis. Anemia and
B-type natriuretic peptide are significant laboratory variable that predict mortality. Two
dimensional echocardiography and tissue Doppler imaging measurements including left
ventricular ejection fraction, E/Ea ratio ≥ 15, restrictive transmiral filling (deceleration time
£ 140 ms) and Em < 3.5 cm/s are predictors of adverse outcomes in diastolic HF patients.
(Cardiol J 2011; 18, 3: 222–232)
Key words: diastolic heart failure, heart failure with preserved ejection fraction
and mortality
Introduction
Diastolic heart failure (DHF) is a clinical syn-
drome defined by the presence of symptoms and
signs of heart failure (HF), preserved ejection frac-
tion (EF), and abnormal diastolic function [1]. Dia-
stolic dysfunction refers to an abnormality of dia-
stolic distensibility, filling, or relaxation of the left
ventricle [2]. DHF is also known by other terms
such as heart failure with preserved ejection frac-
tion (HFPEF) or HF with preserved systolic func-
tion, which describe patients with symptoms and
signs of HF with normal EF. Objective evidence for
diastolic dysfunction is not necessary in using these
terms. It is estimated that approximately half of all
patients with HF have a preserved EF [3]. Although
the prevalence of HFPEF has been increasing, the
survival of this group of patients has not improved
over the past several decades [4].
The syndrome is associated with significant
morbidity. Studies have shown a similar length of
hospitalization, decline in functional status, and re-
hospitalization in patients with HFPEF compared
to patients with HF and reduced EF [5, 6]. The
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mortality in patients with HFPEF is reported to be
as high as the mortality in patients with HF and
depressed systolic function, although a few reports
have suggested better survival in patients with
HFPEF. The mortality rate for patients with DHF
is reported to be 5–8% annually compared to 10–
–15% in patients with depressed systolic function,
whereas the mortality for age-matched controls ap-
proaches 1% [1]. In a nested case control study, the
mortality among patients with HF and normal EF
was 8.7%, as compared with 3.0% among matched
control subjects [7]. In a study of 413 patients hos-
pitalized for HF with EF ≥ 40% from March 1996
through September 1998, a similar number of
deaths were observed among patients with pre-
served EF compared to those with depressed EF
at the end of a six month follow-up (13% vs 21%,
p = 0.02) [6]. There was no difference in the rates of
functional decline among those with preserved and
depressed EF (30% vs 23%, respectively; p = 0.14).
No significant difference was seen in the risk of
readmission (hazard ratio [HR] 1.01, p = 0.96) or
the odds of functional decline or death (odds ratio
[OR] 1.01, p = 0.97). The results from this study
highlight the significantly high absolute burden from
mortality and morbidity associated with HFPEF.
Tribouilloy et al. [8] described the long-term
prognosis of HFPEF in patients hospitalized for
a first episode of HF. During a five year follow-up,
370 (56%) patients died. Patients with HFPEF had
significantly lower five year survival than the age-
and sex-matched general population (43% vs 72%).
Five year survival rates were not significantly dif-
ferent in patients with preserved and reduced EF
(43% vs 46%, p = 0.95). Both groups had similar
relative five year survival rates compared to the
general population. The study concluded that
HFPEF has a poor prognosis, comparable with that
of HF with reduced EF, with a five year survival
rate after a first episode of 43% and a high excess
mortality compared to the general population.
In a population based study, Bhatia et al. [9] re-
ported an unadjusted mortality rate of 5% in patients
with an EF > 50% compared to 7% in patients with
EF < 40% at 30 days (p = 0.08) and at one year (22%
vs 26%, p = 0.07), respectively. Adjusted one-year
mortality rates were also not significantly different
in the two groups (HR 1.13, p = 0.18). The rates of
readmission for HF and of in-hospital complications
did not differ between the two groups. The survival
of patients with HF with preserved EF was similar
to that of patients with reduced EF.
Other reports have suggested a favorable prog-
nosis in patients with HFPEF compared to those
with HF with depressed systolic function. The Irbe-
sartan in Heart Failure with Preserved Ejection
Fraction (I-Preserve) trial annual mortality was
5.2% in patients with HFPEF [10]. The mortality
rates in patients with HFPEF/DHF in epidemiolo-
gical studies and randomized clinical trials are sum-
marized in Table 1 and Table 2, respectively. The
varying mortality rates are driven by numerous fac-
tors including study designs, patient age, EF crite-
ria, and outpatient or inpatient study population.
Patients with DHF tend to be older, more female,
with a higher prevalence of hypertension and less
coronary artery disease (CAD) compared to patients
with HF and reduced EF [3, 11].
In patients with DHF, cardiovascular (CV) dis-
eases (60%) are the leading cause of death includ-
ing sudden cardiac death (26%), HF (15%), myo-
cardial infarction (5%) and stroke (9%) followed by
non-CV causes (30%) and unknown (10%) [3]. The
prognostic factors in patients with HF and de-
pressed systolic function are well understood. How-
ever, there remains uncertainty regarding impor-
tant prognostic factors in patients with HFPEF.
Knowledge of these important clinical and biologi-
cal variables will help identify subgroups of patients
at very high risk for adverse outcomes. There is
limited data from well designed studies regarding
effective treatment strategies for HF patients with
diastolic dysfunction. In this review, we describe
from the literature the demographic, clinical and
laboratory variables that significantly affect the out-
comes of patients with DHF.
Hypertension
Hypertension is one of the greatest risk fac-
tors for diastolic dysfunction. Through a variety of
mechanisms, including increased afterload, left ven-
tricular hypertrophy, myocardial fibrosis and im-
paired diastolic filling, hypertension may lead to
subsequent HF. Diastolic dysfunction is believed to
be a ‘pathophysiological intermediate’ between hy-
pertension and HF. Studies have indicated that
echocardiographic evidence of diastolic dysfunction
is an independent risk factor for the future deve-
lopment of HF and cardiac death [12].
In a cross-sectional study from Olmsted Coun-
ty, Minnesota, USA, 20.8% of participants had mild,
6.6% had moderate, and 0.7% had severe, diastolic
dysfunction, with 5.6% having moderate or severe
diastolic dysfunction with normal EF. The presence
of mild diastolic dysfunction (HR 8.31, p £ 0.001) and
moderate to severe diastolic dysfunction (HR 10.17,
p £ 0.001) was associated with marked increases in
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all-cause mortality [13]. Better blood pressure con-
trol leads to significant reduction in the development
of new HF. The results from the Systolic Hyperten-
sion in the Elderly Program (SHEP) evaluated the
role of anti-hypertensive agents to prevent HF in
4,736 patients with a history of isolated systolic hy-
pertension, randomized to chlorthalidone vs place-
bo or atenolol vs matching placebo in a step-care plan.
This stepped care treatment of hypertension led to
a significant reduction in the development of new HF.
The relative risk (RR) reduction was approximately
50% (RR 0.51, p < 0.001) [14].
Data from the Anti-Hypertensive Lipid Low-
ering to Prevent Heart Attack Trial (ALLHAT)
showed that chlorthalidone significantly reduced the
incidence of new onset HFPEF compared to lisino-
pril. However, the effects of chlorthalidone and lis-
inopril on reducing the incidence of HF with re-
duced ejection fraction were similar [15].
Adequate blood pressure lowering improves
diastolic dysfunction irrespective of the type of anti-
hypertensive medications. The hypothesis that ren-
nin–angiotensin–aldosterone system (RAAS) block-
ing agents improve diastolic dysfunction more sig-
nificantly than other anti-hypertensive medications
was evaluated in a study of patients with hyperten-
sion, left ventricular ejection fraction (LVEF) > 50%
and evidence of diastolic dysfunction [16]. Patients
were randomly assigned to receive either the angio-
tensin receptor blocker (ARB) valsartan or a matched
placebo. Patients in both groups were also treated
with other anti-hypertensive agents that did not
block RAAS. There was no significant difference in
blood pressure reduction in either group. However,
diastolic relaxation velocity increased by 0.60 cm/s
from baseline in the valsartan group (p < 0.0001) and
by 0.44 cm/s in the placebo group (p < 0.0008) at
the end of 38 weeks of treatment. The study con-
cluded that among patients with hypertension and
diastolic dysfunction, lowering blood pressure im-
proves diastolic function irrespective of the type of
anti-hypertensive.
Clinical trials in HFPEF and DHF
There is limited data from well-designed ran-
domized clinical trials (RCT) regarding the effec-
tiveness of numerous therapeutic agents in patients
with DHF. Overall, various agents including angio-
tensin converting enzyme inhibitor and ARB, which
have been shown to improve mortality in patients
with HF and reduced EF, did not show similar re-
sults in patients with HFPEF. A brief review of the
RCTs in patients with DHF is presented in Table 2.
Perindopril in Elderly Patients with Chronic
Heart Failure (PEP-CHF) was the first RCT to eva-
luate the role of adding perindopril to diuretics in
patients with HF and preserved LV function. Eld-
erly patients ≥ 70 years with a diagnosis of HF,
LVEF of ≥ 45% and echocardiographic features
suggesting possible diastolic dysfunction were ran-
domized to receive perindopril at 4 mg/day or a pla-
cebo. The study showed no difference in mortality
or HF hospitalization [17].
The Candesartan in Heart Failure Assessment
of Mortality and Morbidity (CHARM) preserved tri-
al showed that candesartan did not reduce mortality
in patients with symptomatic HF and preserved
LVEF. However, there was a significant reduction
in re-hospitalization for HF in the candesartan group
(230 vs 279, p = 0.017). Three thousand and twenty
three patients with a history of congestive heart fail-
ure, New York Heart Association (NYHA) class
II–IV symptoms and LVEF > 40% were randomly
assigned to candesartan vs matching placebo in 1999–
–2000. Patients were on other anti-hypertensive
agents as well in both arms. At the end of a 36.6 month
median follow-up, there was no difference in CV
deaths in both groups (170 vs 170) [18].
The ancillary Digitalis Investigation Group
(DIG) study evaluated the role of digoxin in patients
with HFPEF > 45%. In a mean follow-up of
37 months, digoxin did not reduce the risk of death
from any cause, or hospitalization for a CV cause,
compared to a placebo. However there was a trend
in reducing the risk of hospitalization for worsen-
ing HF (HR 0.79, p = 0.09) [19].
Most recently, the Irbesartan in Heart Failure
with Preserved Ejection Fraction (I-Preserve) trial
randomized 4,128 patients, aged 60 and above, NYHA
class II–IV HF symptoms, LVEF ≥ 45%, to receive
irbesartan 300 mg/d vs placebo. Annual mortality was
5.2% in the study. There was no difference in mor-
tality in irbesartan vs placebo (HR 0.95, p = 0.35).
Irbesartan did not reduce the primary endpoints of
death and protocol-specified CV hospitalizations,
nor did it significantly benefit pre-specified second-
ary endpoints. For this large group of patients con-
stituting half of all HF patients, there continues to
be no specific evidence-based therapy [10].
Predictors of mortality in patients
with HFPEF and DHF (Table 3)
Demographics
Age has been recognized as one of the most
important determinants of prognosis in patients
with DHF. The approximate five-year mortality rate
226
Cardiology Journal 2011, Vol. 18, No. 3
www.cardiologyjournal.org
in patients with DHF who were < 50 years has been
reported to be 15%. For those aged 50–70 years it
is 33%, and for > 70 years it approaches 50% [1].
Older age and male gender were recognized as im-
portant predictors of death in patients with HFPEF
enrolled in the Digitalis Investigation Group (DIG)
trial. The adjusted hazard ratio for one standard de-
viation increase of age was 1.28, p = 0.0019 and ha-
zard ratio for male gender was 1.71, p = 0.0005.
Other determinants of mortality were impaired re-
nal function and worse functional class [20].
There is evidence that patients of non-Cauca-
sian ethnicity have an increased risk of developing
HF with preserved EF and poorer outcomes than
Caucasian patients. In a study by O’Connor et al. [21],
non-Caucasian ethnicity was a predictor of morta-
lity in patients with HF and EF > 40%. There were
21% non-Caucasian patients in this study. These
findings emphasize the importance of better under-
standing of the disease process in ethnic minorities
in order to improve outcomes.
Coronary artery disease
The presence of CAD is known to increase the
risk of developing HFPEF and is also associated
with increased mortality. Several studies have sug-
gested that the prevalence of CAD in HFPEF is
lower than that in HF and reduced EF. Among
52,187 patients hospitalized for acute decompensat-
ed HF, the prevalence of CAD in HFPEF was re-
Table 3. Predictors of mortality in patients with diastolic heart failure.
Clinical parameter Risk estimates
Age
For every SD increase in the age2 [20] HR 1.28, p = 0.0019
5 year mortality [1]:
< 50 years 15%
50–70 years 33%
> 70 years 50%
Male gender [20] HR 1.71
Caucasian race (adjusted risk ratio) [21] RR 0.75
Coronary artery disease (adjusted risk ratio) [21] RR 1.1
AF
Five-year survival sinus rhythm vs AF [25] 72% vs 56%, p = 0.0001
LVEF ≥ 55% 62% vs 78%, p < 0.0001
LVEF 41–54% 57% vs 72%, p = 0.02
LVEF ≥ 55% (n = 5130) HR 1.29, p = 0.0002
Anemia (relative risk of death) [32] HR 1.57, p = 0.015
BNP
Adjusted OR to predict mortality [37] OR 2.23, p < 0.0001
To predict the cardiac mortality and Chi-square =17, p < 0.0001
CHF re-hospitalization [39]
Pre-discharge BNP (for death and re-admission) HR 1.14 (95% CI 1.02–1.28), p = 0.027
(after adjusting for clinical variables) derivation study [38]
Pre-discharge BNP level > 350 ng/L related to death HR 12.6 (95% CI 5.7–28.1), p = 0.0001
or readmission (validation study) [38]
Echocardiographic parameters:
LVEF
10% reduction in the EF below 45% [44] Risk for total mortality increased by up to 39%
E/Ea ratio ≥ 15
Cardiac mortality and CHF re-hospitalization [39] Chi-square = 13.6, p = 0.0001
Restrictive transmitral filling
DT £ 140 ms [46] HR 2 (95% CI 1.1–3.4), p = 0.02
Em < 3.5 cm/s [48] HR 5.29 (95% CI 2.64–10.60)
HR — hazard ratio; OR — odds ratio; RR — risk ratio; CI — confidence interval; CHF — congestive heart failure; DT — deceleration time;
EF — ejection fraction; BNP — brain natriuretic peptide; AF — atrial fibrillation
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ported as 50%, while in patients with reduced EF
it was 59% (p £ 0.0001) [5].
O’Connor et al. [21] described the prognostic
significance of CAD in a study of 2,498 consecutive
patients with NYHA class II to IV symptoms and
EF > 40%. Sixty five per cent of the patients had
CAD while 62% had a history of hypertension. The
median LVEF was 58% and the overall five-year
mortality for the total study population was 28%.
In multivariate Cox proportional hazard models, the
strongest predictors were age, NYHA class IV
symptoms, and CAD index. Other important pre-
dictors included diabetes, peripheral vascular dise-
ase, and minority ethnic group.
Atrial fibrillation
Atrial fibrillation (AF) is common among pa-
tients with diastolic dysfunction. The study from
Olmsted County, Minnesota showed 41% preva-
lence of AF among patients with HF and preserved
EF [22]. Age adjusted five-year risk of AF was found
to be 12%, 14%, and 21% in patients with abnormal
relaxation, pseudonormal and restrictive diastolic
filling, respectively [23].
Rusinaru et al. [24] evaluated the relation be-
tween AF and long-term survival in patients with
HFPEF. Three hundred and sixty eight patients
with a first episode of HFPEF were followed for five
years. The prevalence of AF was 36% in this study
population. Patients with AF were older and more
often had hypertensive heart disease. AF was as-
sociated with an excess mortality mainly related to
advanced age. On univariate analysis, AF was as-
sociated with increased five-year mortality (HR
1.36, p = 0.03). After adjustment for the co-mor-
bidities, baseline AF was not a predictor of long-
-term mortality.
A subgroup analysis of the CHARM study eva-
luated the effect of AF and risk of clinical events in
HF patients with and without LV systolic dysfunc-
tion [4]. Patients were divided by baseline EF
(£ 40% or > 40%) into low or preserved EF groups.
Patients with AF and preserved EF had a higher risk
for adverse CV outcomes (34% with CV death or
HF hospitalization) relative to those with preserved
EF and sinus rhythm (21%). After covariate adjust-
ment, AF at baseline remained an independent pre-
dictor of all-cause mortality regardless of baseline
EF. Also, absolute risk of CV death or HF hospita-
lization increased from 20% to 47% by the new de-
velopment of AF in the preserved EF group.
Similarly, Pai and Varadarajan [25] investigat-
ed the prognostic implications of AF as a function
of LVEF in 8,931 consecutive patients undergoing
echocardiography. The prevalence of AF was 11% in
patients with normal LVEF (≥ 55%, n = 5,130), and
18% each in those with mild reduced LVEF (41–54%,
n = 1,209). The effect of AF on five-year survival
was most pronounced in those with normal LVEF
(62% vs 78%, p < 0.0001) followed by those with
a mild reduction in LVEF (57% vs 72%, p = 0.02).
The discordant results regarding the prognos-
tic significance of AF in HFPEF might be due to
a different patient population in these studies. The
impact of loss of atrial kick might be different among
the patients with LVEF > 50 compared to those
with slightly reduced EF 40–50%. In the study by
Rusinaru et al. [24], the patients had LVEF > 50
while the CHARM study included all patients with
EF > 40%. Furthermore, the impact of AF might
also depend on the etiology of diastolic HF. Raunso
et al. [26] found that in patients with HF with a his-
tory of CAD, chronic AF was associated with an in-
creased risk of death. There was no increased mor-
tality in patients with HF and chronic AF who did not
have ischemic heart disease. This study showed a sig-
nificant interaction between the etiology of HF and
the prognostic importance of chronic AF (p = 0.003).
Mamas et al. [27] carried out meta-analysis of
the prognostic significance of AF in HF [27]. They
looked at 16 studies, of which five studied patients
with preserved LVEF. Analysis of the pooled data
from three of these studies showed 35.3% morta-
lity in patients with HF and AF compared to 20.3%
mortality in patients with HF and normal sinus
rhythm (p < 0.0001). None of these studies ad-
dressed the etiology of mortality however, so
whether this excess mortality was due to HF,
stroke, CAD or a non-cardiac cause remains un-
clear.
Anemia
Anemia is a common co-morbidity in patients
with HF and is defined by the WHO as a hemoglo-
bin level below 12 g/dL in women and below 13 g/dL
in men [28]. A large community study, based on In-
ternational Classification of Diseases ninth revision
(ICD9) codes, estimated that 58% of patients with
HF had anemia of chronic disease [29]. In a sub-
study of the CHARM program, the prevalence of
anemia in patients with preserved and systolic EF
was similar: 27% and 25%, respectively. In the
CHARM sub-study, there were 133 vs 69 deaths and
527 vs 352 hospitalizations per 1,000 patient-years
of follow-up in anemic patients vs non-anemic pa-
tients (p < 0.001) [30].
The exact underlying mechanisms regarding
the causes of anemia and increased mortality in
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patients with HF are not well understood. Some of
the proposed etiologic mechanisms include hemodi-
lution causing a state of ‘pseudoanemia’, defective
iron utilization, renal dysfunction, insufficient eryth-
ropoietin production, neurohormonal and proinflam-
matory cytokine activation causing anemia of chro-
nic disease [28]. The increased mortality observed
in HF patients with anemia is also complex, with
interplay between many confounding factors. Very
high hemoglobin levels (≥ 17 g/dL) or very low le-
vels (< 13 g/dL) are associated with significantly
higher risk of death and re-hospitalization for HF
regardless of the level of systolic function [31].
Tehrani et al. [32] concluded that the presence
of anemia was associated with increased five-year
mortality in patients with DHF. They reported the
results from a retrospective analysis of 294 patients
with HF and preserved LVEF ≥ 50%, of whom 162
had anemia as defined by the WHO definition. In
the same study, elderly patients (> 75 years) with
diastolic HF and anemia had higher mortality rates
and worse outcomes. The presence of anemia did
not influence re-hospitalization during a mean fol-
low-up of 3.3 ± 1.8 years in this study.
Kerzner et al. [33] in a study of 359 hospita-
lized HF patients did not find a correlation between
hemoglobin level and mortality in very elderly pa-
tients (≥ 75 years). The lower hemoglobin did pre-
dict worse survival in patients who were younger
than 75 years.
In this study, 43.5% of patients had preserved
LVEF (≥ 40%). Hemoglobin was divided into three cat-
egories: 41% of patients had hemoglobin < 11.5 g/dL;
38.4% had hemoglobin of 11.5–13.4 g/dL; and 17.5%
had hemoglobin ≥ 13.5 g/dL [33].
Despite growing evidence regarding the prog-
nostic significance of anemia in HF patients, there
are no practice guidelines regarding the assessment
and management of anemia in HF. The use of iron
supplements and erythropoietin-stimulating agent
to target the hemoglobin 11.0–12.0 g/dL is only
considered in patients with concomitant chronic
kidney disease as outlined by the National Kidney
Foundation KDOQI guidelines [34].
B-type natriuretic peptide
B-type natriuretic peptide (BNP) is a neurohor-
mone synthesized by the ventricular myocardium
that plays an important role in volume homeosta-
sis [35]. It is released in response to myocardial wall
stretch, either by increased volume or pressure. It
helps prevent volume overload by inhibiting the
RAAS and initiating natriuresis, diuresis and vasodi-
latation [36]. Recent studies have evaluated the
prognostic value of plasma BNP level alone or in
combination with echocardiographic parameters in
patients presenting with decompensated DHF.
The role of plasma BNP to predict in-hospital
mortality in acute decompensated HF was evaluat-
ed in 48,629 patients from the ADHERE (Acute
Decompensated Heart Failure National Registry)
database. The BNP was measured within 24 hours
of the presentation of patients for acute decompen-
sated HF. In-hospital mortality was assessed by
BNP quartiles in the entire cohort and in patients
with both reduced LVEF < 40% (n = 19,544) as
well as preserved LVEF ≥ 40% (n = 18,164) and
LVEF > 50% (n = 12,631). It was reported that
there was a near-linear relationship between BNP
quartiles and in-hospital mortality for the entire
cohort: (Q1 [1.9%], Q2 [2.8%], Q3 [3.8%], and Q4
[6.0%], p < 0.0001). BNP quartiles independently
predicted mortality in patients with both reduced
and preserved systolic function, and these findings
for BNP and mortality were independent of signi-
ficant clinical and laboratory variables (adjusted
OR 2.23, p < 0.0001) [37].
Logeart et al. [38] evaluated the prognostic
value of serial BNP assay for the prediction of ear-
ly death or re-admission for HF in patients hospi-
talized for HF exacerbation. In this study, 114 pa-
tients were included from the derivation study and
109 from the validation study. Plasma BNP mea-
surements were obtained upon hospital admission
and subsequently on the day of discharge, or on the
day before discharge. All patients also underwent
Doppler echocardiograms to assess LVEF, Doppler
mitral inflow pattern and systolic pulmonary artery
pressure. High pre-discharge BNP level was the
most significant predictor of short-term death or re-
admission after an acute exacerbation. The study
also showed that the prognostic information of pre-
discharge BNP assay was greater than most com-
mon clinical variables and Doppler echocardiogra-
phic findings.
Dokainish et al. [39] reported that pre-dis-
charge BNP levels and tissue Doppler derived
transmitral early diastolic velocity/tissue Doppler
early diastolic annular velocity E/Ea ratio in patients
who had been admitted for acute exacerbation of HF
were strong predictors of cardiac mortality and re-
admission for HF.
Echocardiographic parameters
The American Heart Association and the
American College of Cardiology recommend initial
clinical assessment of patients with HF using two-
-dimensional echocardiography with Doppler to as-
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sess LVEF, LV size, wall thickness, and valve func-
tion [40]. Echocardiography not only provides
diagnostic information regarding LV function and
valvular dysfunction, its parameters can be used for
prognostic value as well [41, 42].
Left ventricular ejection fraction
LVEF is a widely used clinical measure to as-
sess LV function and has been shown to predict
mortality in HF patients with low EF [43]. The rela-
tionship between a wide range of LVEF and both fatal
and non-fatal outcomes was assessed in 7,599 pa-
tients enrolled in the CHARM study population [44].
The mean LVEF was 38.8 ± 14.9%. The study con-
cluded that LVEF predicts mortality with overall
better survival in patients with increasing EF up to
45%. For each 10% reduction in the EF below 45%,
the risk for total mortality increased by up to 39%.
Mitral flow velocities
and tissue Doppler imaging
Doppler recordings of ventricular filling veloci-
ties, and more recently tissue Doppler imaging
(TDI) derived parameters, have been studied for
prognosis in patients with systolic and diastolic HF
[39, 45]. Akkan et al. [46] evaluated the prognostic
value of deceleration time (DT) in 972 patients with
symptomatic HF. Restrictive transmitral filling, as
defined by DT £ 140 ms, was an independent pre-
dictor of mortality at 51 months of follow-up. For
patients with LVEF ≥ 50, hazard ratio for DT £ 140
was two (confidence interval: 1.1–3.4, p = 0.02).
Moller et al. [47] studied pseudonormal and
restrictive filling patterns in patients with myocar-
dial infarction. Echocardiography was performed in
125 patients with first myocardial infarction within
24 hours. Normal filling was defined as DT 140 to
240 ms and color M-mode flow propagation veloci-
ty (Vp) ≥ 45 cm/s. Impaired relaxation was DT
≥ 240 ms; pseudonormal filling was DT 140 to 240 ms
and Vp < 45 cm/s; and restrictive filling was DT
< 140 ms. During a follow-up of 12 ± 7 months,
33 patients died. No patients with normal filling pat-
tern died. Five patients with impaired relaxation,
11 patients with pseudonormal filling, and 17 pa-
tients with restrictive filling died during the follow-
up. Pseudonormal filling pattern, a restrictive fill-
ing pattern and Killip class ≥ II proved to be inde-
pendent predictors of cardiac death. LVEF did not
provide independent prognostic information after
the LV filling pattern was included in the model.
These results indicate that assessment of LV fill-
ing patterns provide superior prognostic informa-
tion, compared to systolic variables.
Tissue Doppler imaging measures the veloci-
ty of the myocardium during the cardiac cycle. Early
diastolic velocity measured at mitral annulus (Ea)
or myocardial segments (Em) are relatively preload-
insensitive and reflect myocardial relaxation. Wang
et al. [48] evaluated the incremental value of TDI
for prognosis in addition to standard mitral flow
velocity in patients with hypertension and left ven-
tricular hypertrophy. The pseudonormal and re-
strictive filling patterns were associated with car-
diac mortality. Em was the most powerful predic-
tor of cardiac death. Em < 3.5 cm/s provided the
prognostic utility incremental to clinical information
and standard echocardiographic parameters of left
ventricular hypertrophy and diastolic filling pattern.
Incremental predictive power of TDI was eval-
uated in a small study of 110 patients with HF [39].
This study included patients with LVEF < 35%
(54 patients), 36% to 49% (15 patients) and LVEF
≥ 50% (41 patients). Ratio of transmitral flow to ear-
ly mitral annulus diastolic velocity (E/Ea) and BNP
were among the significant predictors of re-hospitali-
zation for HF or cardiac death. BNP ≥ 250 pg/mL
and mitral E/Ea ≥ 15 had incremental predictive
power, to which conventional predictors, such as
LVEF and mitral flow velocity, did not add further
prognostic information.
In another study of 239 consecutive patients
admitted for acute coronary syndrome who under-
went echocardiography, the ratio of early transmi-
tral flow to early mitral annulus velocities was cal-
culated. At two year follow-up, ratio of transmitral
flow to early mitral annulus velocity ≥ 15 was an
independent predictor of cardiac death [49].
In summary, pseudonormal flow pattern, re-
strictive flow pattern, Em < 3 cm/s and E/Ea ≥ 15
provide independent prognostic information in pa-
tients with both systolic and diastolic HF and pa-
tients with a history of myocardial infarction and
hypertensive heart disease. These parameters pre-
dict cardiac mortality. Further studies are needed
to understand the mechanisms underlying these
findings, and whether they derive from HF morta-
lity or sudden cardiac death.
Electrocardiograms and Holter parameters
There are differences in electrocardiogram
(ECG) parameters in patients with DHF vs those
with systolic HF [50]. Patients with DHF are re-
ported to have more AF, a slower heart rate, short-
er QRS (102 ± 35 ms vs 122 ± 41 ms, p < 0.001)
and shorter QTc interval than patients with systol-
ic HF. The prevalence of left bundle branch block
(LBBB) was reported as 25% in patients with HF.
230
Cardiology Journal 2011, Vol. 18, No. 3
www.cardiologyjournal.org
However, among patients with LVEF ≥ 40%, the
prevalence of LBBB was reported as 12.3% [51].
The presence of complete LBBB was associated
with a 70% increase in all-cause mortality in pa-
tients with HF. The impact of LBBB on mortality
in patients with HFPEF remains unknown.
There have been reports of novel Holter pa-
rameters regarding their prognostic significance in
patients with HFPEF. Cygankiewicz et al. [52] eval-
uated 112 patients with HF and preserved LV func-
tion for heart rate turbulence (HRT). Abnormal
HRT was found in 49% of patients. The mean val-
ues of turbulence onset and slope in this group of
patients were 0.87% and 6.05 ms/RR, respective-
ly. Abnormal HRT reflected the severity of the HF.
In another study of 651 patients, 24-hour Holter
monitoring was performed to assess the prognos-
tic value of QT/RR slope on mortality in patients
with HF [53]. Forty four per cent of patients had
LVEF > 35%. Increased QT/RR slopes were inde-
pendently associated with increased total mortali-
ty. Further studies are needed to evaluate the roles
of abnormal HRT and QT/RR slope on mortality in
patients with HFPEF.
Cardiac resynchronization therapy (CRT) is
currently limited to those with LVEF £ 35%. There
has been growing interest in evaluating the role of
CRT in patients with DHF. A recent retrospective
analysis from the PROSPECT trial evaluated the
predictors of response to CRT in patients with HF
and LVEF > 35%. The study showed that patients
with LVEF > 35%, NYHA functional class III–IV
symptoms, and QRS > 130 ms appeared to derive
clinical and structural benefit from CRT [54]. Pen-
icka et al. [55] demonstrated a reduction in dyssyn-
chrony, and an improvement in functional class and
exercise capacity, with the use of CRT in patients
with DHF. CRT, a valuable option for patients with
DHF and LBBB, should be formally tested in a pro-
spective, randomized multi-center trial.
Summary and conclusion
Diastolic heart failure currently accounts for
more than 50% of all HF cases. The mortality and
morbidity in patients with DHF is comparable with
those of patients with reduced EF. Pharmacologic
agents that have been shown to benefit patients
with HF and reduced EF have failed to show simi-
lar results in DHF patients. However, the manage-
ment of these patients should include the treatment
of hypertension, maintenance of normal sinus
rhythm, and the prevention of myocardial ischemia
and diabetes mellitus [56]. There is a need for ex-
ploration of novel treatments and strategies, includ-
ing medications, ECG, Holter parameters and car-
diac implantable devices, in DHF patients. One such
possibility is the newer anti-anginal drug ranolazine
which blocks inward sodium current and reduces
intracellular calcium. Ranolazine could potentially
emerge as a treatment for DHF.
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